In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...

Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell ...

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...

This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas ...

Treatment for stage 3 myeloma is typically divided into phases. The goal is to achieve a deep remission, meaning the cancer ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent ...

Scientists at the Icahn School of Medicine at Mount Sinai, in partnership with the Multiple Myeloma Research Foundation (MMRF) and in collaboration with leading institutions across the country, have ...

The map was developed by using single-cell RNA sequencing to analyze 1.4 million plasma and immune cells in bone marrow from over 300 patients.

By a News Reporter-Staff News Editor at Stem Cell Daily-- Investigators publish new report on Oncology- Multiple Myeloma. Our ...

Researchers at WashU Medicine and their collaborators have created an immune cell atlas of multiple myeloma, a cancer of the ...